Fluciclovine (18F)
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Fluciclovine (18F) |
| DrugBank ID | DB13146 |
| Brand Names (EU) | Axumin |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 97.86% |
Approved Indication (EMA)
This medicinal product is for diagnostic use only. Axumin is indicated for Positron Emission Tomography (PET) imaging to detect recurrence of prostate cancer in adult men with a suspected recurrence based on elevated blood prostate specific antigen (PSA) levels after primary curative treatment.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | trichotillomania | 97.86% | DL |
| 2 | Tourette syndrome | 97.70% | DL |
| 3 | migraine disorder | 97.25% | DL |
| 4 | migraine with brainstem aura | 96.81% | DL |
| 5 | erectile dysfunction (disease) | 96.31% | DL |
| 6 | postural orthostatic tachycardia syndrome | 96.09% | DL |
| 7 | multifocal atrial tachycardia (disease) | 95.64% | DL |
| 8 | His bundle tachycardia | 95.52% | DL |
| 9 | idiopathic neonatal atrial flutter | 95.19% | DL |
| 10 | hyperthyroidism | 94.55% | DL |
| 11 | multiple endocrine neoplasia | 94.17% | DL |
| 12 | atypical coarctation of aorta | 93.94% | DL |
| 13 | cauda equina syndrome | 93.65% | DL |
| 14 | hyperthyroxinemia | 93.59% | DL |
| 15 | resistance to thyroid hormone due to a mutation in thyroid hormone receptor beta | 93.51% | DL |
| 16 | anaphylaxis | 93.25% | DL |
| 17 | atrophoderma vermiculata | 93.17% | DL |
| 18 | thyroid gland disease | 93.10% | DL |
| 19 | open-angle glaucoma | 92.98% | DL |
| 20 | ulerythema ophryogenesis | 92.75% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.